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Remarkable progress in the treatment of heart disease is 
chronicled by the remarks of the distinguished plenary 
session speakers who have addressed the College during the 
past 10 years (Table 1). Recently, fibrinolysis has proved to 
be a particularly powerful means of treating patients with 
acute myocardial infarction. Accordingly, in this year’s 
address, it is a privilege to discuss some of the novel and 
significant contributions of molecular biology to the progress 
in coronary thrombolysis. 
Results from Washington University that will be presented 
reflect vigorous efforts by many colleagues. In addition, we 
have had extensive help from numerous talented and gracious 
collaborators from centers throughout the world, such as 
Desire Cohen at the University of Leuven. To paraphrase 
John Zinman, a director of the Wills Physics Laboratory of 
the University of Bristol, they have made our activities in the 
molecular biology and biochemistry of coronary thrombolysis 
a joyful experience in the tradition of research he described as 
“a romance of discovery-a creative enterprise in which the 
only enemy is ignorance” (I). 
Coronary thrombolysis is a long-standing concept. Liq- 
uefaction of the blood has been recognized for more than a 
century. The fibrinolytic properties of streptokinase were 
identified more than 50 years ago. Thus, we must ask, why 
has enthusiasm been delayed until relatively recently? Sev- 
eral paradigm shifts have punctuated the change. Working 
with Eugene Braunwald and colleagues at the University of 
California at San Diego, who demonstrated that infarct size 
could be reduced by diminution of myocardial oxygen re- 
quirements and that infarction was a dynamic process, we 
and others (2) showed that the extent of infarction was an 
important determinant of prognosis. In elucidating the phe- 
nomenon of coronary spasm, Attilio Maseri and coworkers 
showed that coronary angiography was safe, even in patients 
with an acute coronary syndrome. Soon after, Rentrop and 
colleagues documented recanalization after streptokinase in 
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patients with acute evolving infarction, and DeWood and 
coworkers convincingly documented a high prevalence of 
coronary thrombosis in patients with transmural infarction. 
In concert, these observations lent impetus to the burgeon- 
ing enthusiasm for coronary thrombolysis-an enthusiasm 
fed also by rapid progress in molecular biology (3). 
Until recently, the revolution in molecular biology that 
has had such a profound impact on medicine in general has 
been felt only peripherally in our cardiovascular subspe- 
cialty. However, the harnessing of genetic engineering to 
produce thrombolytic drugs with promising properties now 
benefits patients with heart disease (4). Several practical 
pharmacologic targets can be approached by genetic engi- 
neering in the design of even more powerful thrombolytic 
agents. They include relative clot selectivity, increased 
efficacy of recanalization, increased safety, lack of antige- 
nicity, altered half-life in the circulation and therapeutic 
synergistic interactions. 
The history of coronary thrombolysis has been punctu- 
ated by several milestones pertinent to products of the new 
biology. Elucidation of the biochemical structure and mech- 
anisms of action of activators, purification of tissue-type 
plasminogen activators (t-PA), cloning of the t-PA gene and 
angiographic documentation of recanalization in pilot studies 
set the stage for multicenter large scale efforts involving 
literally thousands of investigators during the past several 
years. 
Coronary Thrombolysis 
Theoretical Considerations 
First generation thromholytic agents. Clot lysis occurs 
when plasminogen, a circulating protein that associates 
avidly with thrombi, is converted to plasmin, a proteolytic 
enzyme that hydrolyzes fibrin. Physiologically, the conver- 
sion is mediated by t-PA elaborated from endothelial cells 
juxtaposed to intravascular clots. Early efforts to induce 
thrombolysis utilized streptokinase and urokinase, so-called 
first generation thrombolytic agents. These activators con- 
vert circulating as well as thrombus-associated plasminogen 
to plasmin with equal alacrity. Physiologic modulation of the 
fibrinolytic system relies on inhibitors such as alpha-2 anti- 
plasmin and fast-acting plasminogen activator inhibitor type 
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Table 1. American College of Cardiology Opening Plenary 
Addresses During the Past Decade 
Fluid (Plasma) Phase 
Year Speaker Address 
Plasminogen ?? t-PA + [Pg - t-PA] ---?- Plasmin + I-PA 
A 
m k., Ik, -K, - 
1979 H.J.C. Swan Impedance Reduction and Heart Failure 
65 PM 
1980 Harriet P. Dustan Hypertension 
1981 Eugene A. Stead The Cardiologist and Society 
1982 Alexander S. Nadas Pulmonary Hypertension 
1983 John Ross. Jr. Ventricular Function and Contractility 
Fibrin Domain (Thrombus) 
1984 Edgar Haber Antibodies in Cardiology v kl kz 
1985 Edmond H. Sonnenblick The Treatment of Heart Failure 
Pfasminogen * t-PA - 
T [ 1 Pg - I-PA M t-PA + Plasmin ?? Fibrinolysis I ‘fibrin’ 
1986 Stephen E. Epstein Hypertrophic Cardiomyopathy k.,/k, -K, - .14pM 
1987 Norman E. Shumway Heart and Heart-Lung Transplantation 
1988 Douglas P. Zipes Cardiac Electrophysiology 
1 (PA&l) that attenuate fibrinolytic activity by diverse 
mechanisms. 
Second generation thromholytic agents. After t-PA had 
been isolated and purified in pharmacologic quantities by 
Collen et al. (5), it became clear that second generation 
thrombolytic agents differed markedly from first generation 
agents. When thrombolysis is induced with a first generation 
agent, circulating plasminogen is converted to plasmin, with 
consequent degradation of circulating proteins, such as 
fibrinogen and plasminogen, as well as degradation of pro- 
coagulants involved in the defense against systemic bleed- 
ing. In contrast. second generation agents preferentially 
convert plasminogen associated with thrombi to plasmin, 
hence inducing clot lysis without plasminemia and with 
relative sparing of fibrinogen, as well as avoidance of degra- 
dation of circulating proteins including procoagulants re- 
quired for hemostasis (6). 
Clot selectivity. The implications of preferential conver- 
sion of clot-associated compared with circulating plasmino- 
gen to plasmin by second generation agents are striking. Clot 
selectivity may confer protection against systemic bleeding 
by precluding marked elevation of concentrations of circu- 
lating fibrinogen degradation products and marked degrada- 
tion of procoagulants required for hemostasis. In addition, 
the property of relative clot selectivity may result in an 
increased incidence of recanalization. 
Plasminogen in plasma is in equilibrium with plasminogen 
in the domain of fibrin (Fig. 1). Accordingly, a first genera- 
tion agent such as streptokinase that markedly consumes 
plasma plasminogen may concomitantly deplete plasmino- 
gen from thrombi. Under such circumstances, conversion of 
clot-associated plasminogen to plasmin may be attenuated. 
Consequently, recanalization may be limited. In contrast, a 
second generation agent such as t-PA that preferentially 
interacts with plasminogen associated with fibrin (indicated 
by the values of K, in Fig. 1) does not markedly consume 
circulating plasminogen. Hence, it can elicit clot lysis with- 
out leaching plasminogen from clots, thereby avoiding po- 
tential attenuation of sustained intense fibrinolysis. 
Figure 1. The hypothesis of competition. Equilibrium between 
plasminogen in the fluid (plasma) phase and plasminogen (Pg) 
associated with clots can hypothetically result in depletion of 
clot-associated plasminogen when the concentration of plasminogen 
in plasma declines. First generation agents invariably diminish 
circulating plasminogen markedly. In contrast. second generation 
agents such as tissue-type plasminogen activators (t-PA) interact 
much more avidly with plasminogen associated with fibrin, as 
reflected by the lower K, value shown for fibrin domain interactions 
compared with interactions between t-PA and plasminogen in 
plasma. Accordingly, depletion of plasminogen from plasma by t-PA 
is much less marked than is the case with first generation agents and, 
consequently. the likelihood of depletion of plasminogen from the 
fibrin domain is diminished substantially. As a result, plasminogen 
remains available for activation to form plasmin in the fibrin domain, 
with consequent persistence of intense fibrinolysis. k,, kk, and kz 
are unidirectional rate constants. 
Results of Initial Studies With Second 
Generation Agents 
In initial studies of naturally occurring human t-PA given 
to dogs with induced coronary thrombi, which we performed 
with Desire Collen in 1983 (7), prompt lysis of the coronary 
clots, reperfusion of myocardium and restoration of inter- 
mediary metabolism delineated by positron emission tomog- 
raphy were documented. Sparing of fibrinogen and plasmi- 
nogen was evident in contrast to the case with equieffective 
doses of urokinase. Subsequently, we obtained similar re- 
sults in dogs given t-PA produced by recombinant DNA 
technology (8). 
Initial human studies of coronary thrombolysis. In our 
initial study (9) of patients with myocardial infarction given 
naturally occurring t-PA, prompt coronary thrombolysis was 
seen in more than 80%. The agent used was melanoma cell, 
supernatant fraction, human t-PA. The dose was modest 
(~12 mg). During infusion of t-PA. clot lysis occurred 
without appreciable diminution of plasma fibrinogen or plas- 
minogen. In contrast, when streptokinase was subsequently 
administered in conventional therapeutic doses, marked 
depletion of both fibrinogen and plasminogen was evident. 
Encouraged by these initial results with naturally occur- 
ring t-PA, investigators at our institution in collaboration 
with those at Johns Hopkins, the University of Leuven and 
the Massachusetts General Hospital performed a pilot study 
852 SOBEL JACC Vol. 14, No. 4 
CORONARY THROMBOLYSIS AND THE NEW BIOLOGY October 1989:850-60 
(10) sponsored by Genentech. Recombinant DNA-produced 
t-PA (rt-PA) was administered in a double-blind, placebo- 
controlled fashion to patients with angiographically docu- 
mented coronary thrombosis. Recanalization was elicited by 
rt-PA in >75% of patients. Perhaps of even more impor- 
tance, intravenous rt-PA appeared to be as effective as 
intracoronary rt-PA. At about the time this study was 
completed, Peter Rentrop (11) summarized the results of 
recanalization trials in which pre- as well as postinterven- 
tional angiograms were available from patients who had been 
given streptokinase. His compilation showed that despite the 
then conventional wisdom to the contrary, intravenous 
streptokinase recanalized only approximately 50% of infarct- 
related arteries. In concert, these observations supported 
the view that genetically engineered clot-selective agents 
such as rt-PA might not only be less prone to perturb 
hemostatic mechanisms, but also more effective in recana- 
lizing infarct-related arteries when given intravenously. 
TIMI-I trial. The National Heart, Lung, and Blood In- 
stitute-sponsored Thrombolysis in Myocardial Infarction 
(TIMI-I) trial compared r&PA with streptokinase. Its results, 
published in 1985 (12), demonstrated that a genetically 
engineered, relatively clot-selective agent, recombinant 
DNA-produced plasminogen activator (rt-PA), was twice as 
effective as streptokinase in recanalizing infarct-related ar- 
teries both 30 and 90 min after the onset of treatment. In 
addition, the results demonstrated that recanalization was 
more frequent with rt-PA compared with streptokinase, 
regardless of the interval after the onset of symptoms 
preceding treatment with either of the two agents. 
European Cooperative Study Group trial. In the same 
year, Marc Verstraete and colleagues (13) in the European 
Cooperative Study Group reported results of an angiograph- 
ically documented, double-blind, streptokinase and rt-PA 
comparative trial that were remarkably concordant with 
results of the TIMI-I trial. In the pooled results from the two 
studies, the superiority of the relatively clot-selective agent 
rt-PA was evident, regardless of whether treatment was 
started within 3 h after the onset of symptoms or later. 
Risks of Bleeding 
In a subset of patients from the European Cooperative 
Study Group trial, analysis of fibrinogen-sparing was per- 
formed (14). Consistent with results from our pilot study (9), 
the initial Genentech-sponsored trial (10) and the TIMI-I 
study (12), depletion of fibrinogen was much more marked in 
patients given streptokinase compared with those given the 
recombinant DNA-produced, relatively clot-selective agent 
rt-PA. 
Incidence of hemorrhagic stroke. Despite the theoretical 
advantages of relative clot selectivity, it has been difficult to 
determine definitively whether relatively clot-selective 
agents are safer than first generation thrombolytic agents, in 
Table 2. The Incidence of Cerebrovascular Accidents During 
Thrombolytic Therapy in Recent Large Trials 
Agents and Trials 
No. of 
Patients 
No. of 
Events % 
SK and APSAC 
(GISSI, PAIMS, ISIS-2) 
SK and APSAC, placebo 
(GISSI, PAIMS, ISIS-2) 
tt-PA (ASSET, ECSG 
[two trials], TIMI-II) 
&PA, placebo (ASSET, 
ECSG [two trials]) 
Total 
Active 
Placebo 
14,954 I26 0.84 
14,949 I26 0.84 
6,500 50 0.76 
2,861 21 0.94 
21,454 176 0.82 
17,810 153 0.86 
APSAC = anisoylated plasminogen streptokinase activator complex; 
ASSET = Anglo-Scandinavian Study of Early Thrombolysis (28); ECSG = 
European Cooperative Study Group (13); GlSSl = Gruppo Italian0 per lo 
Studio della Streptochinasi nell’htfarto Miocardico (26); ISIS-2 = Second 
International Study of Infarct Survival (27); PAIMS = Plasminogen Activator 
Italian Multicenter Study (17); r&PA = recombinant tissue-type plasminogen 
activator; SK = streptokinase; TIMI-II = Thrombolysis in Myocardial 
Infarction Trial: Phase II (29). 
part because of concomitant use of anticoagulants and 
antiplatelet drugs that may obscure differences attributable 
to the fibrinolytic agents themselves. Despite sometimes 
intense concern about the most catastrophic potential com- 
plication of thrombolytic drugs (namely, hemorrhagic 
stroke), the incidence of cerebrovascular accidents early 
after myocardial infarction is no higher with either first or 
second generation agents than with placebo, judging from 
results of large scale trials in which ascertainment is virtually 
complete. Thus, as shown in Table 2 with results from 
>39,000 patients (1.5), the incidence rate is 0.94% in patients 
treated with either streptokinase or anisoylated plasminogen 
streptokinase activator complex (APSAC) and 0.76% among 
those treated with rt-PA. Both values are comparable with 
the incidence rate of 0.82% seen in placebo group control 
patients from the same studies who were given no throm- 
bolytic agent (Table 2). 
Streptokinase vs. r&PA. Fortunately, the incidence of 
cerebrovascular accidents does not appear to be increased 
by treatment with either first or second generation throm- 
bolytic agents in appropriately selected patients with myo- 
cardial infarction. However, potential overall advantages of 
clot selectivity with respect to safety have been suggested by 
analysis of the incidence of bleeding from all sites in some 
trials. For example, in results from the European Coopera- 
tive Study Group trial (13), the incidence of bleeding from 
nonvascular access sites appeared to be greater in patients 
treated with streptokinase compared with rt-PA, as did the 
incidence of hematoma at catheterization sites and the need 
for transfusion (Fig. 2). 
To date (4), four studies (13,1618) have directly com- 
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t-PA (64) SK (65) 
Figure 2. The incidence of bleeding in the European Cooperative 
Study Group trial (13). As can be seen, more patients among the 65 
treated with streptokinase (SK) compared with the 64 treated with 
tissue-type plasminogen activator (t-PA) required transfusions and 
the incidence of bleeding unassociated with vascular access sites 
was more than four-fold greater in those treated with streptokinase 
as opposed to t-PA. 
pared streptokinase with the genetically engineered, rela- 
tively clot-selective agent rt-PA (Fig. 3). The incidence of 
bleeding unrelated to sites of vascular access was fourfold 
greater with streptokinase than with rt-PA. judging from the 
pooled results of these four trials. The statistical significance 
of the difference in pooled data from these four studies is 
<O.OOl, with a Pearson chi-square value of 13.71. 
Coronary Patency 
A second potential advantage of relative clot selectivity 
consequent to molecular engineering of thrombolytic agents 
is increased efficacy. After the encouraging results of the 
TIMI-I and European Cooperative Study Group trials, sev- 
Figure 3. The incidence of major bleeding (unrelated to vascular 
access) in four trials in which tissue-type plasminogen activator 
(t-PA) and streptokinase (SK) were compared directly. The inci- 
dence of bleeding was four-fold higher in patients treated with 
streptokinase compared with those treated with t-PA in these trials. 
The difference was highly significant (p < 0.01) as determined by 
Pearson chi-square analysis. Data obtained from four trials: TIMI-I 
(12), ECSG-I (13), PAIMS (17) and Doreut et al. (18). Fibrinogen 
decrease in 3 h averaged 57% (SK) and 267~ (t-PA) with bleeding 
correlating with FDP elevations (Rao et al.) in TIMI-I. 
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Figure 4. Patency of infarct-related arteries in patients treated with 
streptokinase (SK), tissue-type plasminogen activator (t-PA) or 
anisoylated plasminogen streptokinase activator complex in trials in 
which angiographic end points have been employed. Patency rates 
were substantially higher for patients treated with t-PA compared 
with those treated with the other agents. The difference is highly 
significant (p < 0.01) based on Pearson chi-square analysis. Ander- 
son ??= reference 20. 
era1 large scale, highly publicized trials (4) of coronary 
thrombolysis were undertaken. Figure 4 summarizes results 
from all available, large scale, angiographically documented 
studies; patency of infarct-related arteries 90 min after the 
onset of treatment appears to be substantially greater when 
rt-PA is used, as opposed to either streptokinase or APSAC. 
Results with this clot-selective agent are significantly better, 
with a p value of <O.OOl and a chi-square value > 123 judging 
from analysis of the pooled results of these studies 
(13.16,19-25). 
Mortulity and the Bene$t of Aspirin 
Results of four clinical trials. The landmark Gruppo Ital- 
iano per lo Studio Della Streptochinasi nell’Infarto Mio- 
cardico (GISSI) study (26) demonstrated in a large number of 
patients that the mortality rate could be reduced substan- 
tially by administration of streptokinase in patients with 
acute myocardial infarction. A reduction in the early mor- 
tality rate of as much as 50% was seen in patients treated 
within the 1st h after the onset of symptoms. It is difficult, 
however, to determine whether specific thrombolytic agents 
reduce the mortality rate differentially, in part because of 
disparate regimens used in different studies, potential dis- 
similarities among included patients and the relatively low 
mortality rate associated with modern treatment of acute 
myocardial infarction. As Cohen and Gold (26a) have 
pointed out, even if one thrombolytic agent was 50% more 
effective in recanalizing an infarct-related artery than an- 
other, a comparative trial involving >lO,OOO patients would 
be needed to detect an anticipated difference in the mortality 
rate resulting from the actual difference in efficacy of reca- 
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Figure 5. The early mortality rate (within 30 days) among patients 
treated with streptokinase (SK) or tissue-type plasminogen activator 
(t-PA) with or without aspirin in four large-scale trials of coronary 
thrombolysis. The mortality rate was lower in patients treated with 
t-PA with or without aspirin in comparison with those treated with 
streptokinase and similarly stratified. Although the individual trials 
did not compare streptokinase to t-PA, the positive benefit of aspirin 
is evident with either agent, as are differences in survival between 
agents. References: GISSI (26); ISIS-2 (27); ASSET (28); TIMI-IIB 
(29). 
nalization. Nevertheless, it is instructive to compare results 
of recently completed large scale trials of different throm- 
bolytic agents. Figure 5 depicts the absolute early mortality 
rate associated with specific regimens in the GISSI (26) and 
Second International Study of Infarct Survival (ISIS-2) (27) 
streptokinase trials and the Anglo-Scandinavian Study of 
Early Thrombolysis (ASSET) (28) and TIMI-IIB (29) rt-PA 
trials. As can be seen, the mortality rate appears to be 
reduced when aspirin is used in conjunction with either 
thrombolytic agent. In addition, the mortality rate in patients 
treated with rt-PA with or without aspirin appears to be 
lower than that among patients treated with streptokinase 
stratified similarly (Fig. 5). 
Mortality with rt-PA vs. streptokinase. Potential differ- 
ences in the absolute mortality rate attributable to specific 
thrombolytic agents are also evident from analysis of results 
in the patients in the ISIS-2 trial treated with or without 
aspirin alone or in combination with streptokinase (27) and 
those from the recently published European Cooperative 
Study Group (30) of t-t-PA compared with placebo. Despite 
the favorable reductions in the mortality rate evident in 
ISIS-2 with the use of either aspirin, streptokinase or the 
combination of the two compared with placebo, the absolute 
mortality rate was substantially higher for all treatment 
groups in ISIS-2 than in the rt-PA-treated patients in the 
European Cooperative Study Group trial (Fig. 6). 
To date (4), four studies (13,16,17,31) have directly com- 
pared streptokinase and rt-PA from which data pertinent to 
early mortality rates can be extracted (Fig. 7). The mortality 
rate associated with rt-PA was >50% lower than that asso- 
ciated with streptokinase. Judging from the pooled results of 
these trials, the difference was significant, with a Pearson 
chi-square value of 6.18 and a p value of ~0.02. 
15 
9 
‘;: 10 
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Figure 6. I . . lrtality results of the ISIS-2 trial (27) (left) for placebo- 
treated patients, patients treated with aspirin (ASA) alone, patients 
treated with streptokinase (SK) alone or patients treated with 
combinations of the two agents are compared with corresponding 
results from the European Cooperative Study Group (ECSG) trial 
(30) of patients treated with t-PA. The in-hospital mortality rate was 
substantially lower in the t-PA-treated group. 
ECSGS 
Thrombolysis and the New Biology 
The t-PA Molecule 
In view of the already demonstrated promise of geneti- 
cally engineered fibrinolytic agents, let us consider what the 
molecular biology of fibrinolytic agents may portend. Exons 
or coding regions in the t-PA gene specify synthesis of 
specific domains in the expressed protein associated with 
particular functionality. The 527 amino acid t-PA molecule 
contains several domains with specific functions, including a 
fibrin-binding or finger domain, an epidermal growth factor 
domain, a kringle-I domain thought to be involved in inter- 
actions with inhibitors such as PAI-1, a kringle-II domain 
with lysine-binding sites involved in interactions with fibrin 
and a serine protease domain in the B-chain responsible for 
activating plasminogen to form plasmin. The molecule con- 
tains glycosylation sites at amino acids 117, 184 and 448, 
Figure 7. Early mortality rate (within 30 days) in trials in which 
t-PA and streptokinase (SK) were compared directly (13,16,17,31). 
The difference in mortality rates is significant (p < 0.01) based on 
Pearson chi-square analysis, with a 50% lower mortality rate seen 
with t-PA in comparison with streptokinase. 
0 
SK t-PA 
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some of which have been shown by our group and by others 
to be influential determinants in the clearance of t-PA from 
the circulation. 
Mutants of t-PA. The power of molecular biology derives 
in part from the relative ease of synthesis of unique mutants 
with particularly desirable and specific pharmacologic prop- 
erties. In a variant synthesized by oligonucleotide-directed 
mutagenesis in our laboratory (32). the substitution of only 
one base yields a mutant DNA leading to substitution of 
threonine for serine at amino acid 478 in the active site of the 
protein, with consequent diminution of interaction of the 
mutant t-PA with inhibitor and its persistence in the vicinity 
of thrombi and only limited activation of plasminogen. The 
synthesized mutant appears to be particularly promising as 
an imaging agent for coronary and other thrombi in vivo 
because of its high affinity for clots and its persistence after 
binding without degradation of the clot being imaged in 
contrast to the case with high concentrations of labeled 
wild-type t-PA. Thus, it exhibits concentration-dependent 
binding to human clots formed in whole blood in Chandler 
tubes (Fry et al.. unpublished observations). 
Diverse mutants can be synthesized with similar strate- 
gies and with different but highly specific properties. Our 
laboratory has been particularly interested in the pharmaco- 
logic and therapeutic potential of developing agents with 
modified half-lives in the circulation or diminished interac- 
tion with inhibitors. or both. 
Half-Lives and Their Implications 
As shown by data acquired by Devries et al. (33) in our 
laboratory, the disappearance of wild-type t-PA from the 
circulation in experimental animals as well as in human 
subjects is biexponential with an early rapid phase dominat- 
ing. The extraction fraction of t-PA by the liver exceeds 
40%, judging from directly measured arteriovenous differ- 
ences. Prolongation of the half-life of molecularly engineered 
fibrinolytic agents may enhance the efficacy of coronary 
thrombolysis by facilitating consumption of the circulating 
inhibitor by the administered agent and by attenuating 
an otherwise encountered decline in specific functional ac- 
tivity (34). In addition, administration of a smaller overall 
amount of the agent may be required, compared with the 
amount of wild-type t-PA needed to elicit intense and 
prolonged effects. 
When we removed carbohydrate side chains from the 117 
glycosylation site of t-PA enzymatically, there was substan- 
tial prolongation of the half-life of the modified t-PA in the 
circulation (35). This change is consistent with extraction 
under physiologic conditions of circulating t-PA by liver 
macrophages that recognize high mannose constituents. In 
addition, we and others (35) have shown that molecularly 
engineered variants from which the epidermal growth factor 
domain has been deleted exhibit marked prolongation of 
half-life in the circulation. This change is consistent with 
uptake under physiologic conditions of a substantial fraction 
of circulating native t-PA by hepatocytes, shown by Dwain 
Owensby, Alan Schwartz and their colleagues (36,37) at 
Washington University to involve PAI-I as a component of 
receptor-mediated endocytosis. 
t-PA with other agents to enhance intramuscular absorp- 
tion. In studies performed in collaboration with Stanley 
Sarnoff (3839) we explored the possibility that appropri- 
ate modification of the half-life of t-PA in the circulation 
might ultimately facilitate more rapid treatment of pro- 
perly selected and closely monitored patients at high risk. 
Administration of even massive amounts of t-PA intramus- 
cularly in experimental animals leads to virtually no discern- 
ible increase in plasma concentrations for 30 min. However, 
when injection media were supplemented with agents that 
could enhance absorption of intramuscularly administered 
t-PA. an early peak of plasma level of t-PA became evident 
(39). Animals given injections of t-PA with enhancers of 
absorption exhibit virtually no untoward local or systemic 
effects. 
A t-PA mutant to prolong half-life and enhance thrombol- 
ysis. On the basis of the hypothesis that the ratio of the early 
to the late peak of the concentration of t-PA in plasma could 
be increased and that the trough between the two could be 
attenuated if we utilized t-PA with a relatively prolonged 
half-life. additional experiments were performed with a t-PA 
mutant in which the epidermal growth factor domain had 
been deleted. The magnitude of the early peak concentration 
of t-PA in plasma was increased consistently, as was the area 
under the curve throughout the 60 min of observation in 
rabbits given intramuscular injections of t-PA that had been 
genetically engineered to exhibit a prolonged half-life com- 
pared with results after intramuscular administration of 
wild-type t-P,4 (Fig. 8). Because the rate of rise of plasma 
t-PA activity and the maintenance of therapeutic concentra- 
tions in plasma after intramuscular injection are likely to 
reflect not only the rate of absorption but also the competing 
rate of disappearance from the circulation, these results 
indicate that molecular modifications prolonging half-life 
may enhance coronary thrombolysis not only after intrave- 
nous administration of fibrinolytic agents but also after 
intramuscular administration that may permit particularly 
prompt implementation of effective treatment. 
The qficacy qf rt-PA administered intramuscularly 
Hvith enhancers oj’ absorption was demonstrated (38.39) 
in sequential angiograms from dogs with coronary throm- 
bosis induced with a copper coil. Recanalization was 
elicited promptly with intramuscular rt-PA (within 20 
min) and sustained throughout several hours of obser- 
vation despite the lack of administration of anticoagulants 
(38.39). 
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Figure 8. Sequential changes in plasma t-PA activity in rabbits 
given t-PA by intramuscular injection with hydroxylamine and 
methylamine as absorption-enhancing agents. Two types of t-PA 
were used (wild-type t-PA [Activase] and a genetically engineered 
molecular variant [provided by Monsanto] in which the epidermal 
growth factor domain had been deleted so that half-life of the 
molecule in the circulation would be prolonged). The dose of both 
agents was the same (2 mg/kg body weight). Plasma levels rose to a 
higher early peak and were more sustained after administration of 
the variant (triangles) compared with values after administration of 
wild-type t-PA (circles). 
Interactions of t-PA With Platelets 
and Inhibitors 
Interaction of t-PA with platelets. Advances in molecular 
and cellular biology have made it possible to better define the 
nature of complex interactions in the coagulation and fibri- 
nolytic systems, many of which have profound pharmaco- 
logic implications. FitzGerald, Loscalzo and others have 
shown that t-PA interacts with platelets. Data from our 
laboratory (40) suggest that the interaction not only is 
attributable to generation of plasmin, but that it reflects 
effects of the activator on plasma proteins. Thus, no changes 
are seen in surface-labeled platelet-receptors incubated in 
buffers after exposure to pharmacologic concentrations of 
t-PA, though platelets exposed to t-PA in plasma are less 
able to aggregate. Fitzgerald et al (41) have shown that 
exposure of platelets to activators of the fibrinolytic system 
in vivo can induce activation and presumable elaboration of 
factors that can stimulate synthesis of the fast-acting inhib- 
itor of t-PA, PAI-1, in Hep G2 cells (42). 
Interaction of t-PA with inhibitors. As a result of several 
recent observations, we considered the possibility that acti- 
vation of platelets may contribute to early coronary reocclu- 
sion after initially successful coronary thrombolysis because 
of their thrombogenic properties and also because of platelet 
secretion of growth factors that can stimulate synthesis and 
elaboration of inhibitors of fibrinolysis, such as PAI- from 
endothelium and hepatocytes. The activity of t-PA and other 
endogenous activators of fibrinolysis is influenced by persis- 
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tence of the molecule in the circulation and within clots and 
by the extent and intensity of interactions with inhibitors 
(such as PAI-1) that attenuate fibrinolysis (43). Platelets are 
rich in PAI-1, and accordingly, their elaboration of PAI- in 
the vicinity of thrombi undergoing lysis might attenuate the 
effects of endogenous and pharmacologically administered 
fibrinolytic agents. In addition, because they are richly 
endowed with growth factors and because we and others (42) 
have shown that growth factors stimulate liver and endothe- 
lial cells to elaborate PA&l, growth factors elaborated from 
platelets stimulated by t-PA or activated in the vicinity of 
thrombi may augment concentrations of PAI- in the circu- 
lation and locally, thereby attenuating thrombolysis and 
potentiating early reocclusion. 
Inhibitors of fibrinolysis (PAL1) and reocclusion. Our 
implication of PAI- as a factor predisposing to reocclusion 
is based on several observations. The specific functional 
activity of t-PA administered pharmacologically to patients 
declines markedly within 1 h after completion of 6 h thera- 
peutic infusions, evident beginning at hour 7, despite persis- 
tence of high concentrations of administered t-PA antigen in 
the blood at the time the measurements are made (43). The 
decline of specific functional activity is attributable to the 
formation of complexes of the administered t-PA with the 
fast-acting inhibitor (PAI-I), as shown with fibrin autographs 
of sequentially obtained samples. Before infusion of t-PA, 
endogenous t-PA circulates virtually exclusively in a 100 
kDa complex with PAI- 1. During infusion of t-PA, free t-PA 
is prominent, but the formation of complexes with PAI- and 
C,-esterase inhibitor is also evident. After completion of 
infusions of t-PA, free t-PA is virtually absent and circulating 
t-PA antigen is present exclusively in complexes with PAI- 
and other protease inhibitors. 
Under physiologic conditions, clearance of t-PA antigen 
and t-PA activity is concordant. To determine whether a 
dichotomy would result when the concentration of PAI- 
was increased in plasma, Lucore and others in our labora- 
tory (34) performed experiments in rabbits (Fig. 9). When 
the plasma concentration of PAI- is first increased by 
intravenous administration of lipopolysaccharide, bolus in- 
jection of human t-PA is followed by the typical physiologic 
biexponential clearance of antigen; however, a precipitous 
decline in functional activity is seen. The decline in func- 
tional activity is concordant with the decline in concentra- 
tion of free t-PA measured by Western blot analysis (Fig. 9). 
Plasma PAI- activity in acute myocardial infarction: role 
in failure of clot lysis. Armed with the information acquired 
from studies in experimental animals, we characterized 
plasma PAI- activity in patients with acute myocardial 
infarction. Significantly elevated activity was evident com- 
pared with values in control subjects, indicating that plasma 
PAI- increases early after the onset of infarction. Thus, the 
disproportionate decline in functional activity compared 
with the decline in the concentration of circulating antigen 
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Figure 9. Changes in concentrations of t-PA in plasma in a rabbit 
given an intravenous bolus injection of 0.2 mgikg t-PA (Activase) 
after pretreatment with lipopolysaccharide (10 CLg/kg) 4 h previously 
to augment plasma PAI- activity to approximately 200 AU/ml 
(arbitrary units in comparison with physiologic levels of approxi- 
mately 5 AU/ml). In contrast to the case in rabbits given correspond- 
ing injections of t-PA without prior treatment with lipopolysaccha- 
ride, a striking dichotomy was evident between total t-PA 
concentrations measured by ELISA (open circles) and t-PA activity 
measured with a solid phase fibrin microtiter chromogenic assay 
(triangles). The prompt decline in activity despite persistence of 
antigen corresponded to a decline in the concentration of free-t-PA 
(Xs) and was associated with predominance of complexes of t-PA 
with PAI-I evident by fibrin autography and Western blot analysis. 
seen after termination of therapeutic infusions of t-PA in 
patients with infarction appears to reflect formation of com- 
plexes of the activator with endogenous inhibitor. These 
observations led us to hypothesize that apparent failure of 
clot lysis, encountered in some patients, and early reocclu- 
sion of vessels initially recanalized successfully may be 
attributable in part to elaboration of inhibitors of endogenous 
and pharmacologically administered activators of fibrino- 
lysis into the circulation or locally in the vicinity of thrombi. 
Links between platelet activation and inhibition of fibrino- 
lysis. What then are the links between platelet activation 
and inhibition of fibrinolysis in addition to those reflecting 
thrombogenic effects of platelets themselves and elaboration 
of PAL1 from platelet granules? As shown by results ob- 
tained in our laboratory (42), exposure of Hep G2 cells, a 
human hepatoma cell line, to epidermal growth factor in 
concentrations of the same order of magnitude as those seen 
in plasma after release of platelet secretory products led to a 
marked augmentation of secretion of PAI- into the condi- 
tioned media compared with secretion in cells incubated 
under control conditions, as confirmed by immunoprecipita- 
tion and Western blot analysis. This response reflected 
synthesis of messenger RNA (mRNA), as shown in Figure 
10, in which the concentration of PAI-I mRNA is plotted as 
a function of time after exposure of Hep G2 cells to the 
growth factor and compared with PAL1 mRNA content in 
control cells harvested at the same intervals quantified by 
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Figure 10. Increased steady-state concentrations of mRNA for 
PAI-I (the fast-acting inhibitor of t-PA) in Hep G2 cells incubated 
under control conditions or in media supplemented with epidermal 
growth factor (EGF) at a concentration of 5 &ml. Exposure of the 
cells to the growth factor for 3 h led to a marked augmentation of 
mRNA for PAI-1. In contrast, the concentrations of mRNA for 
coagulation factor X and mRNA for glyceraldehyde phosphate 
dehydrogenase (GAP) used as controls did not increase. 
dot blot analysis. Neither mRNA for coagulation factor X 
nor mRNA for glyceraldehyde phosphate dehydrogenase 
used as controls was affected. In addition to the increase in 
the concentration of steady state PAL1 mRNA induced by 
EGF in Hep G2 cells, exposure of the cells to epidermal 
growth factor led to a selective increase in the transcription 
rate of PAI- mRNA demonstrable with nuclear run-on 
studies. 
As shown by Fujii et al. in our laboratory (44), exposure 
of Hep G2 cells to lysates of platelets produced by freezing 
and other treatments led to marked augmentations in steady 
state concentrations of PAI- mRNA, even when Hep G2 
cells were exposed to concentrations of proteins equivalent 
to only 20% of those in plasma after activation of platelets in 
vivo (Fig. 11). Furthermore, medium from platelets acti- 
vated by exposure to collagen exerted comparable effects. In 
additional experiments, exposure of the platelet lysates to 
antibodies to the implicated growth factors prevented stim- 
ulation of synthesis of PAI-1, and intravenous administration 
of growth factors to intact experimental animals augmented 
concentrations of circulating PAL 1 despite the short half-life 
of the growth factors in the circulation. 
A Working Hypothesis 
These results indicate that activation of platelets may 
predispose to early reocclusion or preclude recanalization 
entirely in some patients not only because of their direct 
contributions to thrombosis, but also because of their elab- 
oration of PAI- and growth factors that stimulate PAI- 
transcription and release. In response to platelet activation 
or exposure of platelets to plasminogen activators, the 
elaborated growth factors may stimulate the liver to synthe- 
size and release PAI- into the circulation. Furthermore, 
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Figure 11. Stimulation of the concentration of PAI- mRNA in Hep 
G2 cells by exposure of the cells to platelet lysates and quantifica- 
tion of mRNA by dot blot analysis. Concentrations as low as 10% of 
those anticipated with complete lysis of platelets per ml of plasma- 
augmented PAI- mRNA. PAI-I mRNA increased in a dose- 
dependent fashion in response to increasing concentrations of 
platelet lysates in the incubation media of Hep G2 cells. Ceils were 
harvested after incubation for 3 h. 
growth factors elaborated from platelets may stimulate en- 
dothelial cells in the vicinity of the offending thrombus to 
elaborate PAI- 1, thereby attenuating fibrinolysis and predis- 
posing to early reocclusion of initially recanalized coronary 
arteries. 
The practical implications of this hypothesis are consid- 
erable. Design and development through molecular biology 
of activators of the fibrinolytic system that are relatively 
invisible to inhibitors should preclude some of the untoward 
effects otherwise encountered without an increased risk of 
systemic bleeding. Development of activators devoid of 
interactions with platelets and agents such as monoclonal 
antibodies that can attenuate growth factor-induced augmen- 
tation of circulating and local concentrations of PAI-I may 
well result in more frequent and complete recanalization and 
a diminished incidence of early reocclusion after pharmaco- 
logically induced coronary thrombolysis. 
Fibrinolysis and the practice of cardiology. The impact of 
molecular biology on cardiovascular therapeutics is already 
considerable. Clot-selective agents appear to offer several 
advantages over first generation drugs, including enhanced 
efficacy of recanalization and diminished perturbation of 
hemostatic mechanisms (4,45). We anticipate continuing 
progress predicated on advances in molecular biology. Lim- 
itation of interactions with inhibitors is likely to potentiate 
benefit without increasing risk. Molecular variants with 
modified half-lives may prove particularly useful for the 
treatment of specific syndromes or in specific settings. 
Risk/benefit ratios. Until recently, practitioners of medi- 
cine could select pharmacologic agents for administration to 
their patients largely in terms of the risk/benefit ratio. 
However, the burgeoning costs of medical care have led to 
profound changes in the climate of medical practice. Paul 
Wore CCUs After CCUs Decreased Thrombolysis 
Mb2 
Figure 12. Decreases in the mortality rate of patients with acute 
myocardial infarction managed in the era before the advent of 
defibrillation in coronary care units (CCUs), after widespread utili- 
zation of defibrillation, during the era in which reduction of 
myocardial oxygen requirements (MVO,) was a major focus of 
cardiovascular research and presently for patients treated with 
thrombolysis with t-PA. 
Starr (46) was prescient as well as accurate in his book The 
Social Transformation of American Medicine when he 
wrote: “. . . the rise of [this economic] ethos . . . permeates 
voluntary hospitals, government agencies, and academic 
thought . . . as well as . . . medical care organizations.” 
The high development costs of second generation throm- 
bolytic agents have contributed to cries for rationing of 
medical care. Decisions previously predicated on consider- 
ation of biologic risk/benefit ratios are now increasingly 
made by administrators guided all too exclusively by eco- 
nomic considerations. Unfortunately, the personal physi- 
cian’s view is often denigrated or, at best, disregarded. 
Risk/benefit criteria are often displaced entirely by cost/ 
benefit concerns. In this climate, it is particularly important 
to be thoroughly informed and to serve as patient advocates 
in identifying specific therapeutic regimens needed for opti- 
mal treatment of life-threatening disorders. 
Effect of tbrombolytic therapy on mortality. Three de- 
cades ago, before the advent of defibrillation in coronary 
care units, the early mortality rate among hospitalized pa- 
tients with acute myocardial infarction was as high as 30%. 
In the 196Os, immediate defibrillation lowered the mortality 
rate substantially. Reduction of myocardial oxygen require- 
ments led to further progress in the 1970s with a decline in 
the mortality rate to approximately 12%. Coronary throm- 
bolysis has had an additional salutary impact. As shown in 
the TIMI-II and European Cooperative Study Group trials in 
which coronary thrombolysis was implemented with a rela- 
tively clot-selective, genetically engineered fibrinolytic 
agent, the early mortality rate may be reduced to 55% (Fig. 
12). The 83% reduction in the early mortality rate achieved 
during the past few decades reflects remarkable progress by 
numerous investigators in diverse disciplines. With the in- 
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creasing impact of molecular biology on cardiovascular 
therapeutics, patients can anticipate even further reductions 
in the toll from coronary artery disease in the years to come. 
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